IL7 and neoplasm: Furthermore, the B16-LX/IL-7 vaccine induced a tumor-specific IFN-γ response, as splenocytes or TILs from B16-LX/IL-7-treated mice failed to produce IFN-γ when stimulated with EL-4 tumor cell lysate [28] (Fig. 3).